Holista Colltech Limited (HCT) Fair Value & Analysis
Consumer Defensive · AU · Market cap A$27.2M
Fair value as of: Jun 26, 2026
Analysis
Holista Colltech Limited (HCT) currently trades at A$0.0700, while our model-based Fair Value estimate is A$0.2170 — implying the stock looks roughly 210.0% undervalued today. We read business quality at 80/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Holista Colltech Limited operates as a research-driven biotech company in Australia, Malaysia, and the United States. The company operates through Supplements, Ovine Collagen, Infection Control Solutions, Food Ingredients, and Corporate segments. It manufactures and wholesales dietary supplements; cosmetic grade collagen; infection control solutions; and healthy food ingredients, including low-glycemic index (GI) bread, noodles/pasta, and flatbreads, as well as low-calorie/low-GI sugar substitutes. Further, it offers GI LiTE, a premix glycemic index reducer, and LOGIC, a sweetening solution alternative for health-conscious consumers. The company also offers biogenic particles, low fat chips, and water soluble technology. Holista Colltech Limited is based in Subiaco, Australia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Holista Colltech Limited (HCT) undervalued?
What is the fair value of HCT?
What is the quality score of HCT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.